Otsuka Pharmaceutical Co., Ltd.
Pharmaceuticals
December 7, 2015
Otsuka Files 1xbet 온라인 Approval in Japan 1xbet 온라인 an Additional Indication 1xbet 온라인 the Antipsychotic ABILIFY: Excitability Associated with Juvenile Autism
- An application has been filed with regulatory authorities in Japan 1xbet 온라인 the approval of an additional indication 1xbet 온라인 the antipsychotic ABILIFY, which has been prescribed in Japan since 2006. The additional indication sought 1xbet 온라인 ABILIFY is 1xbet 온라인 excitability associated with autism in juveniles.
- The prevalence of autism in Japan is between 2 and 20 people per 10,000, and the total number of patients is reported as approximately 21,000. Few treatment options exist 1xbet 온라인 the excitability that occurs in about 20% of people with autism and new treatment agents that can be safely used 1xbet 온라인 it are eagerly awaited.
- ABILIFY received approval from the U.S. FDA in 2009 1xbet 온라인 use in patients with excitability associated with autism and in Japan three medical societies active in the field of autism specified the high medical need and expectation 1xbet 온라인 the development of new medicines 1xbet 온라인 autism.
Otsuka Pharmaceutical Co., Ltd. has submitted an application 1xbet 온라인 regulatory approval in Japan of the anti-psychotic drug ABILIFY (generic name is aripiprazole) 1xbet 온라인 the additional indication of excitability associated with autistic disorder 1xbet 온라인 juveniles from ages 6 through 17. The proposed dosage 1xbet 온라인m 1xbet 온라인 the indication is ABILIFY Tablets, 1mg.
Latest Pharmaceutical Bus1xbet 온라인ess related News Releases